S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
S&P 500   3,930.00 (-0.29%)
DOW   33,548.78 (-0.14%)
QQQ   280.83 (-0.30%)
AAPL   140.88 (-1.42%)
MSFT   244.16 (-0.39%)
META   113.93 (-0.17%)
GOOGL   95.73 (-1.29%)
AMZN   87.71 (-0.61%)
TSLA   173.23 (-3.66%)
NVDA   158.86 (-0.63%)
NIO   12.38 (-6.50%)
BABA   87.99 (-3.78%)
AMD   70.45 (+0.26%)
T   19.34 (+0.89%)
MU   53.52 (-0.30%)
CGC   3.37 (-6.65%)
F   13.29 (+0.08%)
GE   85.47 (+0.22%)
DIS   91.95 (-0.37%)
AMC   6.64 (-1.63%)
PYPL   72.61 (+0.53%)
PFE   50.38 (+1.35%)
NFLX   305.56 (+0.00%)
LON:TILS

Tiziana Life Sciences - TILS Share Forecast, Price & News

GBX 58.50
+4.50 (+8.33%)
(As of 10/20/2021)
Add
Compare
Today's Range
45
▼
59
50-Day Range
58.50
▼
58.50
52-Week Range
30
▼
195
Volume
297,127 shs
Average Volume
522,223 shs
Market Capitalization
£113.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
TILS stock logo

About Tiziana Life Sciences (LON:TILS) Stock

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. Its product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. The company also develops anti-IL6R (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients with severe respiratory symptoms. It has a collaboration agreement with FHI Clinical Inc. to conduct a phase 2 clinical trial for treating hospitalized severe COVID-19 patients with intranasal foralumab, a human anti-CD3 monoclonal antibody. The company was incorporated in 1998 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

Receive TILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TILS Stock News Headlines

September 25, 2022 | finanznachrichten.de
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 9, 2022 | benzinga.com
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
July 2, 2022 | proactiveinvestors.com
Tiziana Life Sciences' half-term report reveals it has made progress on all fronts
June 17, 2022 | finance.yahoo.com
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
June 9, 2022 | fool.co.uk
Tiziana Life Sciences
June 7, 2022 | investing.com
Advan Co Ltd (7463)
March 24, 2022 | proactiveinvestors.com
Tiziana Life Sciences: Multiple Sclerosis single study
March 24, 2022 | proactiveinvestors.com
Tiziana Life Sciences: Method of therapy delivery gives firm 'a novel market position'
January 28, 2022 | proactiveinvestors.com.au
2022 update: US listing and fresh data emerging
January 26, 2022 | lse.co.uk
MaxCyte expects improved full-year revenue on organic growth
October 28, 2021 | lse.co.uk
Tiziana Life Sciences Plc Share Chat
October 19, 2021 | finanznachrichten.de
Tiziana Life Sciences Plc: Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital
October 19, 2021 | finance.yahoo.com
Tiziana Life Sciences plc: Court Sanctions the Scheme of Arrangement and approves Reduction of Capital
September 24, 2021 | finance.yahoo.com
Tiziana Life Sciences plc - Interim Results for the Six Months Ended 30 June 2021
September 22, 2021 | proactiveinvestors.com
Tiziana Life Sciences: A different approach, tackling disease using a safe, nasal and oral antibody
September 7, 2021 | finance.yahoo.com
Tiziana to Host Investor Call to Discuss Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
September 3, 2021 | finance.yahoo.com
Tiziana Life Sciences plc Posting of Scheme Document and Notice of Meetings
September 2, 2021 | finance.yahoo.com
TLSA: Foralumab Now in CAR T
August 21, 2021 | finanznachrichten.de
Tiziana Life Sciences Plc: Tiziana Life Sciences plc files scheme of arrangement to effect a corporate reorganisation
August 20, 2021 | benzinga.com
Tiziana Life Sciences plc files scheme of...
August 20, 2021 | proactiveinvestors.com
Tiziana Life Sciences set for Nasdaq move
August 17, 2021 | finance.yahoo.com
Tiziana Announces Publication of a Peer Reviewed Article on Data from the Clinical Trial with Intranasally Administered Foralumab, Its Proprietary Fully Human Anti-CD3 Monoclonal Antibody, in Mild to Moderate COVID-19 Patients in Brazil
August 5, 2021 | proactiveinvestors.com.au
Tiziana Life Science - Second Price Monitoring Extn
August 5, 2021 | proactiveinvestors.com
Tiziana Life Science - Price Monitoring Extension
July 1, 2021 | finance.yahoo.com
TLSA: Intranasal Foralumab in COVID-19
See More Headlines
Receive TILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

TILS Company Calendar

Last Earnings
9/30/2020
Today
12/07/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:TILS
Previous Symbol
LON:ADI
CUSIP
N/A
CIK
N/A
Web
www.tizianalifesciences.com
Phone
+44-20-74952379
Fax
N/A
Employees
11
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
2.36
Current Ratio
6.54
Quick Ratio
6.41

Sales & Book Value

Annual Sales
£-3,595,000.00
Price / Sales
-31.67
Cash Flow
GBX 25.70 per share
Price / Cash Flow
2.28
Book Value
GBX 23.50 per share
Price / Book
2.49

Miscellaneous

Outstanding Shares
194,612,000
Free Float
N/A
Market Cap
£113.85 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Gabriele Marco Antonio Cerrone M.B.A. (Age 49)
    MBA, Founder & Exec. Chairman
    Comp: $13.76M
  • Dr. Kunwar Shailubhai (Age 63)
    CEO, Chief Scientific Officer & Exec. Director
    Comp: $810k
  • Dr. Andrea Brancale
    Scientific Founder
  • Mr. Richard Clarkson Ph.D.
    Scientific Founder
  • Mr. Andrew Westwell Ph.D.
    Scientific Founder
  • Ms. Keeren Shah (Age 44)
    Fin. Director
  • Dr. Thomas H. Adams (Age 78)
    Head of Drug Devel. & Exec. Director
  • Dr. Neil Graham M.P.H. (Age 62)
    MBBS, M.D., MPH, Chief Medical Officer
  • Dr. Napoleone Ferrara (Age 63)
    Chairman of Scientific Advisory Board
  • Prof. Roberto Pellicciari
    Consultant

Key Competitors

View All Competitors













TILS Stock - Frequently Asked Questions

How have TILS shares performed in 2022?

Tiziana Life Sciences' stock was trading at GBX 58.50 on January 1st, 2022. Since then, TILS stock has increased by 0.0% and is now trading at GBX 58.50.
View the best growth stocks for 2022 here.

How were Tiziana Life Sciences' earnings last quarter?

Tiziana Life Sciences PLC (LON:TILS) issued its earnings results on Wednesday, September, 30th. The biotechnology company reported ($2.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($4.00) by $1.40.

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Synergy Pharmaceuticals (SGYP), Micron Technology (MU), ServiceNow (NOW), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Broadcom (AVGO), Dropbox (DBX), Enterprise Products Partners (EPD) and Franco-Nevada (FNV).

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the London Stock Exchange (LON) under the ticker symbol "TILS."

How do I buy shares of Tiziana Life Sciences?

Shares of TILS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Tiziana Life Sciences' stock price today?

One share of TILS stock can currently be purchased for approximately GBX 58.50.

How much money does Tiziana Life Sciences make?

Tiziana Life Sciences (LON:TILS) has a market capitalization of £113.85 million and generates £-3,595,000.00 in revenue each year.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3rd Fl, 11-12 St. James's Square, LONDON, SW1Y 4LB, United Kingdom. The official website for the company is www.tizianalifesciences.com. The biotechnology company can be reached via phone at +44-20-74952379.

This page (LON:TILS) was last updated on 12/7/2022 by MarketBeat.com Staff